|
Working nimbly with a very sticky subject, Adherex Technologies researches and develops cancer treatments. One of its lead drug candidates targets a tumor's blood supply and makes those blood vessels weak and leaky by disrupting a key protein. Other potential therapies could make cancer cells more vulnerable to anti-cancer drugs or help prevent hearing loss in children undergoing certain types of chemotherapy. Adherex Technologies' pipeline is strongly based on compounds that disrupt cadherins, proteins that adhere like molecules together in cell adhesion. Southpoint Capital Advisors own a controlling stake in the company.
|
| | | Contact Information | |
Address: |
4620 Creekstone Dr., Ste. 200
Durham, NC 27703
| | Phone: | 919-484-8484 | | Fax: | 919-484-8001 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 0.00 M | | Employees (2008): | 18 | | Employee Growth (1 yr): | (-5.30%) |
|
|
Key People
| | • |
Chairman:
Robert W. Butts
| | • |
CEO and Director:
Rosty Raykov
| | • |
VP, CFO, and Director:
Robert Andrade
|
|
|
